ChAdOx1-S[recombinant] (COVID-19 Vaccine AstraZeneca) - Food and Drug Administration

ChAdOx1-S[recombinant] (COVID-19 Vaccine AstraZeneca)

On 28 January 2021, the Food and Drug Administration (FDA) issued authorization granting AstraZeneca Pharmaceuticals (Phils.) Inc. the emergency use approval of COVID-19 vaccine ChAdOx1-S[recombinant] (COVID-19 Vaccine AstraZeneca)

Product Information
English Tagalog

Patient Information Leaflet
English Tagalog

The COVID-19 Vaccine AstraZeneca is authorized on the basis of regulatory reliance to the Medicine and Healthcare products Regulatory Agency (MHRA) of the United Kingdom.
Information regarding COVID-19 Vaccine AstraZeneca is being updated regularly and is available here.
Information on the safety of AstraZeneca COVID-19 Vaccine is discussed in their comprehensive Risk Management Plan.
For more information on reporting side effects, click here.